Everything old is new again: the case for imatinib as frontline therapy in 2017
Lee, S.G.; Lipton, J.H.
Clinical Advances in Hematology and Oncology H&o 15(4): 302-305
2017
ISSN/ISBN: 1543-0790 PMID: 28591105 Document Number: 693210
Document emailed within 1 workday
Related Documents
Okuda, H.; Tanaka, H.; Ueno, M.; Shitani, M.; Nasuno, M.; Suzuki, C.; Nishimura, S.; Kimura, H.; Yonezawa, K.; Abe, T.; Yoshida, Y.; Kawabata, M. 2005: A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(12): 1941-1944Rediti, M.; Pellegrini, E.; Molinara, E.; Cerullo, C.; Fonte, C.; Lunghi, A.; Iori, A.; Neri, B. 2014: Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report Anticancer Research 34(2): 905-907
Tsukada, Y.; Tauchi, K.; Nakamura, M.; Kishimoto, H.; Yoshifuku, S.; Otagiri, N.; Sasahara, K. 2010: Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(11): 2181-2184
Shi, R.; Lin, J.; Guo, Y.; Gong, Y.P. 2014: The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells Die Pharmazie 69(5): 346-352
Scheinfeld, N. 2006: Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate Journal of Drugs in Dermatology: Jdd 5(3): 228-231
Sakamoto, Y.; Akimoto, H.; Kojo, M.; Kawano, H.; Chinen, Y.; Morita, K.; Sugiyama, M.; Saeki, H.; Minami, K.; Soejima, Y.; Sakaguchi, Y.; Toh, Y.; Okamura, T. 2011: A case of imatinib-resistant GIST treated by sunitinib Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 827-830
Ioannou, M.; Demertzis, N.; Iakovidou, I.; Kottakis, S. 2007: The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors Anticancer Research 27(2): 1143-1147
Shen, K.-t.; Hou, Y.-y.; Qin, X.-y.; Song, L.-j.; Sujie, A. 2005: Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors Zhonghua Wei Chang Wai Ke Za Zhi 8(2): 129-131
Dika, E.; Barisani, A.; Vaccari, S.; Fanti, P.A.; Ismaili, A.; Patrizi, A. 2013: Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia Journal of Drugs in Dermatology: Jdd 12(5): 512-513
Feki, J.; Marrekchi, G.; Boudawara, T.; Rekik, N.; Maatouq, S.; Boudawara, Z.; Frikha, M. 2015: Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate Gulf Journal of Oncology 1(17): 92-95
Shrestha, N.; Mishra, S.R.; Ghimire, S.; Gyawali, B.; Marahatta, S.B.; Maskey, S.; Baral, S.; Shrestha, N.; Yadav, R.; Pokharel, S.; Adhikari, B. 2021: Health System Preparedness for COVID-19 and its Impacts on Frontline Health-Care Workers in Nepal: a Qualitative Study Among Frontline Health-Care Workers and Policy-Makers Disaster Medicine and Public Health Preparedness 2021: 1-9
Shrestha, N.; Mishra, S.R.; Ghimire, S.; Gyawali, B.; Marahatta, S.B.; Maskey, S.; Baral, S.; Shrestha, N.; Yadav, R.; Pokharel, S.; Adhikari, B. 2021: Health System Preparedness for COVID-19 and its Impacts on Frontline Health-Care Workers in Nepal: a Qualitative Study Among Frontline Health-Care Workers and Policy-Makers Disaster Medicine and Public Health Preparedness 2021: 1-9
Kikuchi, D.; Ishii, Y.; Saitou, M.; Yamada, M.; Takenoshita, S. 2011: A case of gastric gastrointestinal stromal tumor resected after chemotherapy with imatinib Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1201-1204
Nakashima, S.; Fujita, Y.; Matsuo, H.; Ariyoshi, Y.; Fukuda, K.; Fujiyama, J.; Masuyama, M. 2012: Two cases of surgical resection of rectal gastrointestinal stromal tumor after neoadjuvant therapy with imatinib mesylate Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 1932-1934
Molnár, L.; Nagy, A.; Dávid, M.; Szomor, A.ád.; Méhes, G.áb.; Kovács, G.áb.; Losonczy, H. 2004: Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha Orvosi Hetilap 145(17): 901-907
Gelibter, A.; Milella, M.; Ceribelli, A.; Zeuli, M.; Ferraresi, V.; Vecchione, A.; Cognetti, F. 2004: PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients Anticancer Research 24(5b): 3147-3151
Chang, H.; Shih, L-Yung. 2008: Imatinib-induced tumor lysis syndrome: report of a case and review of the literature Chang Gung Medical Journal 31(5): 510-514
Yamamoto, K.; Imamura, H.; Furukawa, H.; Kishimoto, T.; Miyazaki, Y.; Ohshiro, R.; Tatsuta, M.; Ohsato, H.; Fukunaga, M.; Nakayama, T.; Fujimi, S.; Takemoto, H.; Kondo, M.; Kamigaki, S.; Ohta, K.; Nakata, Y. 2006: Neoadjuvant therapy with imatinib mesilate for gastrointestinal stromal tumor of the stomach before subsequent successful surgical resection Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(12): 1875-1877
Jentsch-Ullrich, K.; Pelz, A-Friederike.; Braun, H.; Koenigsmann, M.; Mohren, M.; Wieacker, P.; Franke, A. 2004: Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib Haematologica 89(5): Ecr15
Suzuki, N.; Yoshino, S.; Somura, H.; Ueno, T.; Oka, M. 2009: A case of rapid growth GIST successfully treated with resection after long-term use of imatinib Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(12): 2354-2356